H. Lundbeck A/S
OTC: HLBBF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Charl van Zyl
- Employees
- 5,707
- Headquarters
- Valby, Denmark
- IPO year
- 2022
- Market cap
- $5.2B
- Website
- https://www.lundbeck.com
Loading HLBBF…
Loading profile data…Frequently asked questions about HLBBF
What does H. Lundbeck A/S (HLBBF) do?
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily specializes in therapeutic solutions for psychiatric and neurological disorders across Europe, North America, an...
Where does HLBBF trade?
H. Lundbeck A/S (HLBBF) trades on the Other OTC.
What sector is HLBBF in?
H. Lundbeck A/S (HLBBF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of H. Lundbeck A/S?
Charl van Zyl is the chief executive officer of H. Lundbeck A/S (HLBBF).
Where is H. Lundbeck A/S headquartered?
H. Lundbeck A/S is headquartered in Denmark.
Does HLBBF pay a dividend?
Yes — H. Lundbeck A/S (HLBBF) paid a trailing twelve-month dividend of USD 0.18 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did HLBBF go public?
H. Lundbeck A/S (HLBBF) completed its initial public offering in 2022.